# Clostridium Difficile Vaccine Efficacy Trial

> **NCT03090191** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 17535 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **BIOLOGICAL:** Clostridium difficile vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03090191
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-29
- **Primary completion:** 2021-12-21
- **Final completion:** 2021-12-21
- **Target enrollment:** 17535 (ACTUAL)
- **Last updated:** 2023-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03090191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03090191, "Clostridium Difficile Vaccine Efficacy Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03090191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*